Press Releases

Radiopharmaceuticals Market 2022-2030 With Strategic Trends Growth, Demand & Future Potential Of Industry

Share This Article

On the basis of end-use application, the global radiopharmaceuticals market is divided into two different types, including diagnostic centers and hospitals. Due to substantial availability of competent medical practitioners in hospital radiology departments, hospitals segment is expected to hold considerable share of this market during the forecast period. However, the growing number of diagnostic centers, particularly in developed nations such as the U.S. is likely to propel the global radiopharmaceuticals market forward over the forecast period, from 2021 to 2031

Get the sample copy of report@

Radiopharmaceuticals are a class of radioactive substances that can be employed for diagnostic or therapeutic purposes. Chemicals that emit beta particles (positrons or electrons) or gamma rays are often employed for diagnostic purposes, whereas compounds that release Auger electrons or alpha particles are typically utilized for therapeutic purposes. Radiopharmaceuticals are referred to as “tracers” when they are utilized for diagnostic reasons. The quantity of radiation in diagnostic radiopharmaceuticals is lower than in therapy radiopharmaceuticals.

Radiopharmaceuticals are basically unique therapeutic compositions that incorporate radioisotopes. These radiopharmaceuticals are utilized for both diagnosis and treatment. Radiopharmaceuticals are classified into four different categories, which are radiopharmaceutical preparation, radionuclide generator, radiopharmaceutical precursor, and radiopharmaceutical preparation kit.

Rise in Research and Development Activities is Expected to Drive Demand in the Market

The global radiopharmaceuticals market is driven by the rise in patient awareness, demand for precise diagnosis, increasing demand for disease-targeted cancer therapy, and the growing uses of molecular imaging. The utilization of monoclonal antibodies and radiolabeled peptides for the identification and treatment of malignant tumors (referred to as radiopharmaceutical based customized therapy) is likely to fuel growth of the global Radiopharmaceuticals Market. The market research report examines the radiopharmaceutical sector in further depth, offering a comprehensive view of market dynamics, patient preferences, illness trends, and supply and demand.

In the last few decades, nuclear medicine has acquired a lot of popularity. The availability of 99m Tc, an isotope used in 80% of diagnostic procedures, is primarily responsible for nuclear medicine’s expanding popularity. At present, about 25 million diagnostic procedures involving 99m Tc radiopharmaceuticals are performed yearly, with trends indicating that this number is likely to rise. The availability of short-lived 99m Tc is one of the key factors likely to drive the adoption of Technetium 99. At present, research and development operations are in full swing to boost 99 Mo’s total production capacity, which is expected to have a beneficial influence on 99m Tc output.

Get a glimpse of the in-depth analysis through our Report Brochure

In the current situation, 99m Tc is widely employed in a variety of diagnostic procedures, such as neuroendocrine tumor imaging and thyroid uptake pertechnetate. In the last few years, there has been a tremendous increase in research activity aimed at developing new and better 99m Tc radiopharmaceuticals. 99m Tc is predicted to dominate the global radiopharmaceutical market throughout the forecast timeframe, from 2021 to 20321,as applications of 99m Tc for dynamic and morphological imaging of the liver, kidneys, and bone are expected to rise. In addition, due to their widespread availability and low prices, various radiopharmaceuticals are expected to gain popularity.

View full report@

Increasing Demand for Risk Assessment Services for Cancer Treatment to Drive North America and Europe Markets

North America, Latin America, Asia Pacific, Europe, and Middle East and Africa are the four primary regions that make up the global radiopharmaceuticals market. In 2020, the global radiopharmaceuticals market was headed by North America, trailed by Europe. Due to a rise in PET-CT scanner equipment installations and increased demand for disease risk assessment services for cancer treatment, North America held a large part of the global radiopharmaceuticals market in 2020. From 2021 to 2031, the radiopharmaceuticals market in Asia Pacific is expected to rise at a rapid growth rate. The radiopharmaceuticals market in the region is expected to be driven by product launches, acquisitions, distribution agreements, partnerships, and regional growth by local companies, particularly in India and China.

Key Questions Answered in Radiopharmaceuticals Report

  • What is the sales/revenue generated by radiopharmaceuticals providers across all regions during the forecast period?
  • What are the opportunities in the global radiopharmaceuticals market?
  • What are the major drivers, restraints, opportunities, and threats in the global market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which indication segment is expected to generate the highest revenue globally in 2031?
  • What is the COVID-19 impact on the global market?

Radiopharmaceuticals Market – Segmentation

Purchase Complete Report Now@


  • Fluorine-18 derivatives
  • Fluorine-18 Fludeoxyglucose (FDG)
  • Fluorine-18 Sodium Fluoride
  • Fluorine-18 Flucicovine
  • Fluorine-18 Florbetapir
  • Fluorine-18 Florbetaben
  • Others
  • Technetium-99
  • Lutetium (Lu) 177
  • Gallium-68
  • Dotatate
  • Dotatoc
  • Zirconium 89
  • 11C-choline
  • 14C-urea
  • Others


  • PET
  • Standalone PET Systems
  • Hybrid PET/CT
  • Hybrid PET/MRI


  • Oncology
  • Neurology
  • Neurodegenerative Diseases (AD, PD, and Others)
  • Epilepsy
  • Cardiology
  • Others


  • Hospitals
  • Diagnostic Labs
  • Others


  • North America
  • Europe
  • Asia Pacific
  • Rest of the World


1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Radiopharmaceuticals Market

4. Market Overview

4.1. Introduction & Overview

4.2. Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Opportunities

4.3. Global Radiopharmaceuticals Market Analysis and Forecast, 2017–2031

5. Market Outlook

5.1. COVID-19 Pandemics Impact on Industry

5.2. Key Industry Events

5.3. No. of Nuclear Medicine Centers in Major Countries

5.4. List of FDA Approved Radioisotopes

6. Global Radiopharmaceuticals Market Analysis and Forecast, by Compound

6.1. Introduction & Definition

6.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Compound, 2017–2031

6.2.1. Fluorine-18 Derivatives Fluorine-18 Fludeoxyglucose (FDG) Fluorine-18 Sodium Fluoride Fluorine-18 Flucicovine Fluorine-18 Florbetapir Fluorine-18 Florbetaben Others

6.2.2. Technetium-99

6.2.3. Lutetium (Lu) 177

6.2.4. Gallium-68 Dotatate Dotatoc

6.2.5. Zirconium 89

6.2.6. 11C-choline

6.2.7. 14C-urea

6.2.8. Others

6.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Compound

7. Global Radiopharmaceuticals Market Analysis and Forecast, by Indication

7.1. Introduction & Definition

7.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by Indication, 2017–2031

7.2.1. Diagnosis

7.2.2. Neurology Neurodegenerative Disease (AD, PD, and Others) Epilepsy

7.2.3. Cardiology

7.2.4. Others

7.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by Indication

8. Global Radiopharmaceuticals Market Analysis and Forecast, by System

8.1. Introduction & Definition

8.2. Global Radiopharmaceuticals Market Value (US$ Mn) Forecast, by System, 2017–2031

8.2.1. PET Standalone PET systems Hybrid PET/CT Hybrid PET/MRI

8.2.2. SPECT

8.3. Global Radiopharmaceuticals Market Attractiveness Analysis, by System

9. Global Radiopharmaceuticals Market Analysis and Forecast, by End-user


Purchase Complete Report Now@

You can place an order or ask any questions, please feel free to contact | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

Related Articles

Back to top button